Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
| Distributed by / for | Torrent Pharma Inc. |
| NDC | 13668-116-90 |
| Full product label | LOSARTAN POTASSIUM and HYDROCHLOROTHIAZIDE TABLETS, USP 50 mg/12.5 mg, a) 90-count bottle (NDC: 13668-116-90), b) 1000-count bottle (NDC: 13668-116-10), Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana Inda |
| Recalling firm | Torrent Pharma Inc. |
| Distribution | Nationwide USA and Puerto Rico |
| Quantity | 18,780 bottles |
| Recall initiated | 2018-12-20 |
| Report date | 2019-02-27 |
| Recall completed | — |
| Recall number | D-0505-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Kalamazoo MI United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗